The two-way relationship between cancer and atherosclerosis
Publication date: Available online 1 May 2019Source: Revista Española de Cardiología (English Edition)Author(s): Sergio Raposeiras Roubín, Alberto CorderoAbstractIn the last few years, there has been growing interest in the relationship between cancer and cardiovascular disease. The increase in life expectancy in both diseases has led to their frequent coexistence in the same patient, which can lead to adverse drug reactions that increase patient risk. This is especially relevant in the case of atherosclerosis, which seems to share a common pathophysiological substrate with cancer. In this review, we analyze these common risk factors, and specifically analyze the relationship between different cancer treatments with the risk of coronary or cerebrovascular disease, as well as the current scientific evidence on the possible relationship between antiplatelet therapy and cancer risk. We also review the incidence and prognosis of cancer in patients with atherosclerosis and vice versa, based on the information reported in the most recently published studies in the field of cardio-oncology.ResumenEn los últimos años ha emergido un interés creciente sobre la relación entre el cáncer y las enfermedades cardiovasculares. El aumento de la esperanza de vida de ambas enfermedades ha condicionado su coexistencia cada vez más frecuente en un mismo paciente, con lo cual se ponen de relieve reacciones adversas farmacológica...
Those suffering from cancer, heart conditions, strokes, diabetes and lung disease are among the worst affected by delays to their diagnosis and care, a survey of senior doctors reveals.
The objective of this study was to report the incidence of alopecia arising in patients treated with vismodegib, assessing its characteristics, grade of severity, and time of onset.Skin Appendage Disord
CONCLUSIONS: Surprisingly, the DCR registered fewer patients in 2013-2014 than the DLCR, even though they employ the same primary data source. The agreement between the DCR and the DLCR was 87%; this may be increased to 95% if patients who seemed to meet the inclusion criteria of the other register were also included. The discrepancies found were mainly due to different definitions of dates of diagnosis, registrations probably missed by the algorithms and possible registration errors. Discrepancies resulted in a significant difference in MRR, but not in 1y-RS. FUNDING: none. TRIAL REGISTRATION: not relevant. PM...
CONCLUSIONS: Most women did not experience any improvement in their symptoms over time, and no association was found between lack of symptom improvement and believing that the HPV vaccine was causing the symptoms. FUNDING: funded by the Danish Cancer Society. TRIAL REGISTRATION: not relevant. PMID: 32741432 [PubMed - in process]
Date: Friday, 09 25, 2020; Speaker: Dr. Dauod Meerzaman; Building: Building 10 (Clinical Center); This class is presented as a webinar only; Videocast Event
Date: Wednesday, 05 12, 2021; Speaker: Christine Ambrosone, Ph.D., University of Buffalo; 6100 Executive Boulevard; 3rd Floor Conference Room
Liver Cancer 2020;9:477 –478
Authors: Bera A, Russ E, Srinivasan M, Eidelman O, Eklund M, Hueman M, Pollard HB, Hu H, Shriver CD, Srivastava M PMID: 32744311 [PubMed - as supplied by publisher]
(Wiley) Vaccination against the human papilloma virus (HPV) reduces the risk of a condition that often leads to cervical cancer, according to an analysis of Danish health registry data.
Publication date: Available online 3 August 2020Source: The Annals of Thoracic SurgeryAuthor(s): Filippo Lococo, Giacomo Cusumano, Giuseppe Cardillo